Edition:
United Kingdom

Array Biopharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

10.82USD
8:59pm GMT
Change (% chg)

$-0.25 (-2.26%)
Prev Close
$11.07
Open
$11.09
Day's High
$11.19
Day's Low
$10.69
Volume
570,908
Avg. Vol
933,229
52-wk High
$13.38
52-wk Low
$6.74

Latest Key Developments (Source: Significant Developments)

Array - In Exchange For $126.06 Million 3.00% Convertible Senior Notes Co Issued 2024 $126.06 Million Notes
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA - ‍ON DEC 1, IN EXCHANGE FOR $126.06 MILLION OF 3.00% CONVERTIBLE SENIOR NOTES DUE 2020 CO ISSUED 2024 NOTES OF $126.06 MILLION.ARRAY BIOPHARMA SAYS ‍2024 NOTES WILL MATURE ON DEC 1, 2024​ - SEC FILING.ARRAY - ALSO ISSUED AGGREGATE OF ABOUT 7.96 MILLION SHARES OF CO'S COMMON STOCK IN EXCHANGE OF $126.06 MILLION OF 3.00% CONVERTIBLE SENIOR NOTES DUE 2020​.ARRAY BIOPHARMA - ‍2024 NOTES TO BEAR INTEREST AT 2.625% PAYABLE SEMIANNUALLY IN ARREARS ON JUNE 1 & DEC 1 OF EACH YEAR, BEGINNING JUNE 1, 2018​.  Full Article

Array Biopharma reports initial results from novel immunotherapy combination at SITC annual meeting
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Array Biopharma Inc :Array biopharma reports initial results from novel immunotherapy combination at the Society For Immunotherapy Of Cancer (SITC) 32nd annual meeting.Array Biopharma Inc - ‍plans to expand ongoing phase 2 CSF1R + PD1 combination study into other tumor types including pancreatic cancer​.  Full Article

ARRAY BIOPHARMA REPORTS Q1 LOSS PER SHARE $0.22
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Array Biopharma Inc :ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER OF FISCAL 2018.Q1 LOSS PER SHARE $0.22.Q1 REVENUE $29.7 MILLION VERSUS I/B/E/S VIEW $33.3 MILLION.Q1 EARNINGS PER SHARE VIEW $-0.22 -- THOMSON REUTERS I/B/E/S.‍INCREASE IN QTRLY NET LOSS WAS PRIMARILY DUE TO A DECREASE IN REIMBURSEMENT REVENUE FROM NOVARTIS​.‍INCREASE IN QTRLY NET LOSS WAS ALSO PRIMARILY DUE TO A DECREASE IN NON-RECURRING COSTS FOR COMMERCIAL DRUG SUPPLY FROM NOVARTIS​.  Full Article

Array Biopharma reports financial results for Q2 of fiscal 2017
Thursday, 9 Feb 2017 

Array Biopharma Inc - : Array Biopharma reports financial results for the second quarter of fiscal 2017 . Q2 loss per share $0.14 . Q2 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S . Cash, cash equivalents and marketable securities as of December 31, 2016 were $214.8 million . Says revenue for q2 of fiscal 2017 was $44.5 million, compared to $39.3 million for prior sequential quarter .Says revenue for q2 of fiscal 2017 increased $9.1 million compared to same quarter of fiscal 2016.  Full Article

Array BioPharma Q1 revenue $39.3 mln
Tuesday, 1 Nov 2016 

Array BioPharma Inc : Array BioPharma Inc - Columbus met its primary endpoint in study . Array BioPharma - reimbursement revenue from Novartis was about $129 million for previous 12 months, of which $31.3 million was recorded over past quarter . Array BioPharma reports financial results for the first quarter of fiscal 2017 . Q1 loss per share $0.20 . Q1 revenue $39.3 million versus Thomson Reuters I/B/E/S view $32.5 million .Q1 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.  Full Article

Array Biopharma prices public offering at $6.25 per share
Wednesday, 28 Sep 2016 

Array Biopharma Inc : Array Biopharma announces pricing of public offering of common stock .Says public offering of 18.4 million common shares priced at $6.25 per share.  Full Article

Array Biopharma announces proposed public offering of common stock
Tuesday, 27 Sep 2016 

Array Biopharma Inc : Array Biopharma announces proposed public offering of common stock .Commenced an underwritten public offering of $100 million of shares of its common stock.  Full Article

Array Biopharma enters into note purchase agreement
Friday, 2 Sep 2016 

Array Biopharma Inc : On Sept 2, co entered into note purchase agreement - SEC filing . Notes bear interest at rate of 5 percent per annum . Co issued to Redmile subordinated convertible promissory notes (in aggregate original principal amount of $10 million Source: (http://bit.ly/2c1a5cZ) Further company coverage: [ARRY.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Array Biopharma announces FDA acceptance of Binimetinib for patients with advanced NRAS-mutant melanoma
Thursday, 1 Sep 2016 

Array Biopharma Inc : Announces FDA acceptance Of Binimetinib NDA for patients with advanced NRAS mutant melanoma . Says currently preparing for an application orientation meeting (AOM) with FDA in September 2016 .FDA set target action date under prescription drug user fee act (PDUFA) of June 30, 2017.  Full Article

Array Biopharma files for mixed shelf of up to $300 mln
Thursday, 18 Aug 2016 

Array Biopharma Inc :Files for mixed shelf of up to $300 million - SEC filing.  Full Article

BRIEF-Array BioPharma Announces Redemption Of All Remaining 3% Convertible Senior Notes Due 2020

* ARRAY BIOPHARMA ANNOUNCES REDEMPTION OF ALL REMAINING 3.00% CONVERTIBLE SENIOR NOTES DUE 2020